ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0166

Effect of Air Pollution on Prevalence and Disease Activity of Rheumatoid Arthritis in the German Middle-aged Population from the NAKO Baseline Examination

Tim Filla1, Gamal Chehab1, Jutta Richter2, Jörg Distler3 and Oliver Sander1, 1Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, 2Clinic for Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, Düsseldorf, Germany, 3University Hospital Duesseldorf and HHU, Duesseldorf, Germany

Meeting: ACR Convergence 2025

Keywords: Environmental factors, population studies, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0145–0174) Epidemiology & Public Health Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Environmental influences affect the human body throughout life, from conception to old age. The influence of air pollution and fine dust particles on systemic diseases, particularly rheumatoid arthritis (RA), has been studied in various regions, but has not yet been comprehensively recorded for Germany. Therefore, the aim of this study is to describe the associations between air pollution and the prevalence and disease activity of RA in Germany.

Methods: In the German National Cohort (NAKO) Health Study, medical histories and examination findings were collected from a total of 204,729 individuals (18-69 years of age) in a population sample from 18 study centers between 2014 and 2019. In addition, 23,456 individuals underwent a clinical hand examination of 20 joints for pain and swelling by trained examiners (Level 2 subcohort), enabling the calculation of DAS28 as a measure of rheumatic disease activity. Cumulative and daily air pollution levels were made available for the NAKO study regions by the Environmental Data Unit in Munich (air pollutants (UBA: particulate matter particle size (PM) 2.5, PM10, nitrogen oxide (NO2), and ozone (O3)) to the nearest 1 km from the place of residence on a daily basis; air pollutants (ELAPSE: PM2.5, NO2, O3, black carbon (BC)) to the nearest 100 m for 2010. The analyses were adjusted for age, sex, smoking status, BMI, and income.

Results: RA was known in 4033 individuals of the total cohort (1.97%) and 426 individuals (1.82%) of the Level 2 cohort. Disease activity in the cohort was low (mean DAS28 1.37, standard deviation 1.03). The occurrence of RA was positively associated with age (10-year OR = 1.65 [95% CI: 1.59-1.71]) and female sex (OR = 2.67 [2.46-2.90]). Individuals with RA were on average 57 years old (vs. 50 years old in those without RA), and 71% were female (50%). 39% (vs. 44%) reported never smoking, 36% (vs. 32%) reported previously smoking, and 18% (vs. 20%) were currently smoking.The historical (ELAPSE) and daily (UBA) environmental pollution levels of the respective place of residence showed a strong association with DAS28. Fine dust particle pollution for PM2.5 and PM10, NO2, and BC were positively associated with RA disease activity. In contrast, ozone pollution showed a negative association with disease activity. There was no clinically relevant effect of particulate matter pollution on the frequency of RA for PM2.5 and PM10, NO2, and BC for either the current or historical measurements, although the frequency was lower at higher ozone levels.

Conclusion: A clinically relevant association of disease activity with all air pollutant exposures for RA was demonstrated in the population sample of over 200,000 individuals. However, a relevant association between air pollutant exposure at the current place of residence and the occurrence of RA could not be demonstrated. The cross-sectional results presented here will also be prospectively examined in the NAKO cohort for 20 years to provide stronger conclusions regarding causality, particularly with regard to the different frequencies observed in the study centers.

Supporting image 1Table 1


Disclosures: T. Filla: None; G. Chehab: None; J. Richter: None; J. Distler: 4D Science, 8, 11, Actelion, 2, 6, Active Biotech, 2, 6, Anamar, 2, 6, Array Biopharma, 2, 6, ARXX Therapeutics, 2, 6, aTyr Pharma, 2, 6, Bayer Pharma, 2, 6, BMS (Bristol-Myers Squibb), 2, 6, Boehringer Ingelheim, 2, 6, Celgene, 2, 6, FibroCure, 4, Galapagos, 2, 6, GSK, 2, 6, Inventiva, 2, 6, JB Therapeutics, 2, 6, Medac, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, Redx Pharma, 2, 6, RuiYi, 2, 6, Sanofi-Aventis, 2, 6, UCB, 2, 6; O. Sander: None.

To cite this abstract in AMA style:

Filla T, Chehab G, Richter J, Distler J, Sander O. Effect of Air Pollution on Prevalence and Disease Activity of Rheumatoid Arthritis in the German Middle-aged Population from the NAKO Baseline Examination [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/effect-of-air-pollution-on-prevalence-and-disease-activity-of-rheumatoid-arthritis-in-the-german-middle-aged-population-from-the-nako-baseline-examination/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-air-pollution-on-prevalence-and-disease-activity-of-rheumatoid-arthritis-in-the-german-middle-aged-population-from-the-nako-baseline-examination/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology